Alios BioPharma, Inc. has discovered novel, proprietary, and highly potent nucleoside analogs that are currently in late stage preclinical development for the treatment of chronic hepatitis C.

Due to their broad activity across HCV genotypes and because they exhibit a higher barrier to the selection of drug-resistant virus variants vs. other HCV treatments, nucleoside analogs are emerging as an important component in combination therapy for the treatment of chronic hepatitis C. With excellent potency and selectivity, along with a strong intellectual property estate, the Alios nucleoside portfolio offers a competitive advantage over other existing approaches.

Nucleosides role in the treatment of chronic hepatitis C

Nucleosides exert their activity against the hepatitis C virus by mimicking cellular nucleotides (the building blocks of RNA) and inhibiting RNA synthesis. Through this disruption of RNA production, incomplete and therefore incompetent copies of the hepatitis C viral genome are produced. Nucleoside analogs that have entered development for the treatment of chronic hepatitis C have demonstrated a high barrier to the development of resistance. While nucleoside analogs show great promise for the treatment of chronic hepatitis C, there are a limited number of compounds in development and none have progressed beyond phase II studies.

In order to be active, nucleoside analogs must first be metabolized to the 5’-triphosphate form by cellular kinases in the target cell. The efficiency of these metabolic steps, especially the initial conversion from the nucleoside to the nucleoside monophosphate form, is an important determinant in the efficacy of the compound. Due to this limitation, the first generation of nucleoside analogs entering the clinic for the treatment of chronic hepatitis C required multi-gram dosing levels to be efficacious, and several had to be given twice daily. Given the need for such high and frequent dosing, it is not surprising that most of the first generation nucleoside analogs that entered the clinic were discontinued due to unacceptable safety profiles.

Alios proprietary nucleoside analogs

The Alios clinical development compounds are nucleoside monophosphate prodrugs and thus bypass the need for the formation of the monophosphate form of the nucleoside. As prodrugs, these compounds are expected to be absorbed and penetrate cells more efficiently than their nucleoside counterparts, and the projected doses for these second generation nucleoside analogs are significantly lower than that required for the first generation nucleosides. The Alios compounds have demonstrated excellent oral bioavailability and have the shown the potential to be dosed once daily. These compounds have demonstrated excellent potency against the hepatitis C virus in vitro, and show promising preclinical in vitro and in vivo safety profiles. It is anticipated that the Alios nucleoside portfolio will deliver multiple compounds that will be highly suitable for use in combination treatment of chronic hepatitis C.

About Chronic Hepatitis C

Chronic hepatitis C is a liver disease that results from infection with the hepatitis C virus (HCV) and that currently affects ~170 million people worldwide. HCV infection has two stages, an initial acute stage which may be an asymptomatic, short-term illness, and for 85% of infected individuals, a chronic stage which can progress slowly, without any signs or symptoms for several decades. Chronic infection can lead to liver fibrosis, cirrhosis, end-stage liver disease and hepatocellular carcinoma over a period of 15 to 30 years. Many chronic hepatitis C patients require a liver transplant at late stages of the disease, making HCV infection the most frequent indication for liver transplantation in the United States, Japan and in the European Union.

Interferon based therapy has become the standard of care for the treatment of chronic hepatitis C. While there have been modest advances in improving the tolerability and convenience of interferon-based therapy through Pegylation, the overall efficacy is somewhat limited with <50% of patients infected with HCV genotype 1 achieving a Sustained Virologic Response (SVR). In addition to low response rates, current therapy is associated with numerous side effects. Overall, adverse events result in 10–20% withdrawal from therapy, while an additional 20–30% of patients require dose modifications.

These drawbacks in the current treatment regimen have lead to an active search for new classes of drugs for the treatment of chronic hepatitis C. In recent years there have been significant breakthroughs identifying essential functions within the HCV replication cycle that can be directly targeted for antiviral therapy. The first viral proteins to be clinically validated as therapeutic targets for Direct-acting Antiviral Agents (DAAs) were the NS3/4A protease and the NS5B polymerase. NS3/4A protease and NS5B polymerase are non-structural proteins with well defined enzymatic functions that can be inhibited with small molecules. Similar to what has been achieved against HIV, the advanced development of protease and polymerase inhibitors brings hope for new treatment options for chronic hepatitis C.

When treating viral infections, combination therapy using several drugs with different mechanisms of action has been shown to lead to higher rates of efficacy and better clinical outcomes. It is widely held that nucleoside analog inhibitors of the NS5B polymerase will become critical components of combination therapy for chronic hepatitis C due to their broad activity across the HCV genotypes and because they exhibit a higher barrier to the selection of drug-resistant virus variants vs. other HCV treatments in development. No nucleoside analog has advanced beyond Phase II trials and there is a need to develop additional nucleosides to meet this unmet medical need.

• Home
• About Us
  • Overview
  • Management Team
  • Board of Directors
  • Scientific Advisors
• Technology
  • Overview
  • Activators of innate immunity
  • Nucleoside Analogs
• News Room
  • Press Releases
  • Scientific Publications
• Career Opportunities
  • Overview
  • Research Associate, Respiratory Virology
• Contact Info

Overview Management Team Board of Directors Scientific Advisors

Administrative Assistant & Office Manager THIS POSITION HAS BEEN FILLED Alios BioPharma, Inc. is a biotechnology company located in San Francisco, California that is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system. Alios is pursuing the development of both protein and small molecule therapeutics, each addressing major commercial market opportunities. Alios is discovering and developing novel antiviral agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrugs, and glycoprotein-engineering of interferons (Glycoferon). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). At Alios, our science is the key to our success, and to improving patients' quality of life. Our pipeline of developing novel compounds and investigative therapies reflects our commitment to bring innovative products to patients with unmet needs in the areas of virology. The Position This position will provide main receptionist and corporate administrative support to staff members.  The successful candidate must possess excellent communication skills, both verbal and written, be proactive, quick learner and excel as a team player. Responsibilities: • Effectively use Microsoft Outlook to manage calendars, resolve conflicts, cancellations and calendar follow up as needed • Anticipate and prepare necessary materials to enable successful meetings, appointments, conferences and phone calls • Coordinate and book travel and offsite meetings along with all other required arrangements for the success of the event • Contact external business partners as requested for information, scheduling meetings or miscellaneous follow up; professional phone presence required • Perform general clerical duties to include but not limited to: filing, copying, scanning, faxing, mailing, FedExing and ordering of laboratory and office supplies • Answer incoming calls from company’s main phone line and direct callers as appropriate; professional phone presence required; notify employees of guest arrivals; escort visitors to appropriate senior staff members • Create and modify documents primarily in Microsoft Word, Excel and PowerPoint • Establish and maintain effective hardcopy and electronic document filing/management system • Prepare expense reimbursements, check requests and reconcile credit card receipts to billing statements • Place food orders for occasional lunch meetings; room prep before and tidying up after • Prepare, compile, deliver, track and file regular reports • Other duties as assigned Qualifications and Requirements: • 3+ years of progressive experience as an Administrative Assistant in a fast paced corporate setting (interest in science is a plus) • Top notch Microsoft Outlook capabilities; Strong working knowledge of Microsoft Word, Excel and PowerPoint • Excellent written and verbal communication skills, interpersonal and team player capabilities • Demonstrated ability to be proactive, use independent judgment, discretion and maintain confidentiality • Effective multitasking, attention to detail and strong organizational skills • Strong computer and internet searching capabilities • Comfortable interacting with all levels of the organization Alios BioPharma: Scientist I/II, Nucleoside Chemistry Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Scientist I/II, Nucleoside Chemistry Scientist I/II, Nucleoside Chemistry Alios BioPharma, Inc. is a biotechnology company located in San Francisco, California that is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system. Alios is pursuing the development of both protein and small molecule therapeutics, each addressing major commercial market opportunities. Alios is discovering and developing novel antiviral agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrugs, and glycoprotein-engineering of interferons (Glycoferon). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). At Alios, our science is the key to our success, and to improving patients' quality of life. Our pipeline of developing novel compounds and investigative therapies reflects our commitment to bring innovative products to patients with unmet needs in the areas of virology. Responsibilities:   This is a hands-on, nucleoside specific synthetic chemistry position. The person at this position is expected to independently conduct synthesis of new chemical entities, including design of efficient synthetic routes and chemical structure assignments by NMR and MS spectra. ONLY candidates with experience in synthesis of  nucleosides and nucleotides will be considered. Requirements:   Ph.D. in synthetic organic or medicinal chemistry with 2+ years of experience in synthesis of nucleosides and nucleotides.   Strong publications record (including patents) and demonstrated ability solving challenging synthetic problems Application Process Please send a cover letter and resume to hr@aliosbiopharma.com.  When you respond, please type “Scientist I/II, Nucleoside Chemistry” in the SUBJECT box   Please no recruiters and no calls. Alios BioPharma: Technology Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Technology Alios BioPharma: Activators of innate immunity Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Activators of innate immunity Potent, orally available, broad-spectrum antiviral agents are an unrealized goal of the medical community. Most antiviral therapies directly inhibit viruses, are not broad-spectrum and can lead to drug resistance. In light of the threat of novel emerging viruses (e.g. Pandemic-Influenza), existing medically important viral infections, and the challenges associated with rapid diagnosis of causative agents, treatment with currently available viral specific molecules are suboptimal. Alios’ approach to developing such broad-spectrum antiviral agents has been to study interferon pathways. Interferons are induced in mammalian cells in response to viral infection and represent the first line of defense against these important pathogens. Interferons can be directly administered to patients to treat various viral infections, but they have a number of drawbacks including the need for injections and the non-specific nature of their effects leading to unwanted side effects. In order to retain interferon’s anti-viral effects without the associated side effects, Alios has focused its efforts at the end of one of the pathways that interferons activate, the RNase L system. The 2’5’ oligoadenylate synthetase RNase L system is one of the principal ways in which interferon inhibits virus replication. RNase L is a latent endoribonuclease that is expressed in most cells. In order to activate RNase L, interferon-induced 2’-5’-oligoadenylate synthetases must first make an unusual nucleic acid molecule from ATP called 2-5A. This molecule consists of a series of 5’-triphosphorylated oligoadenylates with 2’-5’ phosphodiester bonds. Trimers and tetramers of 2-5A appear to have only one function, activation of RNase L. Initial binding of 2-5A to the Ankyrin domain of RNase L triggers a conformational change that induces the dimerization of the protein. Subsequently, the active RNase L dimer binds to and cleaves its single stranded RNA substrate at UU and UA residues. This last catalytic step, also called endonuclease activity, is directly responsible for the antiviral effect of the activated RNase L. Activation of RNase L is an ideal target for broad spectrum antiviral drugs since all viruses utilize RNA in their lifecycle. However, 2-5A has a number of pharmacological properties that make it a poor candidate for drug development. To address these deficits, Alios is developing proprietary allosteric activators of RNase L based on structural modeling of the binding of 2-5 A to the activation site of RNase L. To date, in vitro testing has demonstrated that Alios RNase L activators exhibit broad spectrum anti-viral activity against a number of important viruses that cause serious diseases in humans. This broad spectrum of activity highlights the potential of these molecules to revolutionize the treatment of serious viral infections.   Alios BioPharma: Hyperglycosylated Type I Interferons Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Hyperglycosylated Type I Interferons Coming Soon Alios BioPharma: About Us Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors About Us Alios BioPharma: Contact Info Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Contact Info   Business Address: Alios BioPharma, Inc. 260 East Grand Ave, 2nd Floor South San Francisco, CA 94080 (650) 635-5500 (Main) (650) 872-0584 (Fax) For Investor and Media inquiries: press@aliosbiopharma.com For Clinical Development inquiries: clinicaldevelopment@aliosbiopharma.com For Human Resources inquiries: hr@aliosbiopharma.com For Business Development inquiries: bd@aliosbiopharma.com Alios BioPharma: Career Opportunities Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Career Opportunities At Alios, our success depends on our employees and on the strength of our science. The value we have created at Alios is a direct reflection of the talents of each individual whom collectively have come together to develop novel medicines that have the potential to treat viral diseases and increase the quality of life for patients. We are proud of the dedication and accomplishments of all our employees, and we are committed to fostering a working environment that is collaborative, respectful, encourages accountability, expects integrity, rewards performance, and promotes personal fulfillment and satisfaction. Alios’ benefits support our values, our culture, and allow us to attract and retain highly qualified employees. Alios offers a competitive and comprehensive benefit program designed to grow with you and your dependents. Alios employees and their dependents are eligible to participate in Alios’s health plans. Health benefits start on the date of hire or on the first day of the month following employment, depending on the benefit plan. All regular employees qualify for holiday, sick and vacation benefits. Benefits Medical (HMO & PPO), Dental & Vision 401(k) and Employer Contribution Pre-Tax, Medical and Dependent Flexible Spending Accounts Short & Long Term Disability Life and AD&D Insurance Incentive Stock Options: New hire, ongoing, and award grants Company-Wide Holidays, Floating Holidays, and Additional Paid Time Off Employees with one or more years of continuous employment can accrue up to 4.5 weeks vacation time Alios BioPharma, Inc. is seeking professional, talented and highly motivated individuals to work in a positive, energetic and challenging environment. We welcome those who are interested in applying to open positions by sending a resume to Human Resources. PLEASE NOTE: We are currently not accepting calls from outside recruiters or employment agencies. If you would like your contact information in our files for future consideration, please send an e-mail to Human Resources with “Agency for Future Consideration” in the subject line. Alios BioPharma, Inc. is an Equal Opportunity Employer. Alios BioPharma: Press Releases Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Press Releases [body of press release goes here -- use Edit tab to add or edit press releases] Alios BioPharma: Scientific Advisors Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Scientific Advisors Ernest Borden, M.D. Cleveland Clinic Foundation, Director of the Center for Hematology and Oncology Molecular Therapeutics Practicing Oncologist with >20 years research and clinical trials experience with immunomodulatory therapy in cancer Eleanor Fish, Ph.D. University of Toronto, Head, Division of Cellular & Molecular Biology Immunologist, infectious diseases specialist and expert in activation of immune effector cells such as NK cells Heinz Gschwend, Ph.D. Independent consultant Dr. Gschwend has extensive experience with early stage biopharmaceutical and biotechnology companies including his time as Head of Chemistry and Head of Central Research at Ciba Pharma and Head of Research at Arris Pharma (now AxYs). During his career, he was responsible for the development of over eighty clinical candidates, resulting in two drugs currently on the market (Benazepril and Letrozole). Daniel Herschlag, Ph.D. Stanford University, Professor of Biochemistry Dr. Herschlag’s Lab is dedicated to understanding the fundamental behavior of RNA and proteins and, in turn, how these behaviors determine and impact biological catalysis and biology. The lab takes an interdisciplinary approach; spanning and integrating physics, chemistry and biology. Cheng Kao, Ph.D. Indiana University, Professor, Molecular and Cellular Biochemistry Dr. Kao’s team has elucidated how the HCV polymerase recognizes HCV RNAs and initiates RNA synthesis, and his work has direct relevance to anti-HCV drug design. Hans Maag, Ph.D. Independent consultant Dr. Maag has specializes in medicinal chemistry, drug discovery and early clinical development of medicines. He has 35 years of experience in anti-viral drug discovery at Syntex and Roche and has participated and led many project teams, from early drug discovery through preclinical and clinical development, notably resulting in the development and commercialization of Valcyte®. Milton Taylor Indiana University, Professor emeritus Milton Taylor has researched and taught molecular biology at IU since 1967. During this time, he has worked in the areas of somatic cell genetics, viral replication, and the effects of interferon on viral replication and the immune system. Myron Tong, M.D., Ph.D. University of California Los Angeles, Director, Asian Liver Program A world-leading hepatologist, Dr. Tong has specialized in liver-disease research and treatment for more than 25 years. His research efforts include anti-viral treatment of patients with hepatitis B and hepatitis C, and he is heavily involved in the treatment of patients with hepatocellular carcinoma at UCLA. Alios BioPharma: Board of Directors Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Board of Directors Lawrence Blatt, Ph.D., MBA – Founder, President & CEO Dr. Lawrence Blatt has spent the last 28 years working in drug research and development with a specific focus on biology of the immune system, antiviral therapies and relevant therapeutic interventions. From 2002-2008, Dr. Blatt was the Chief Scientific Officer of InterMune, Inc. and led the discovery and development of Danoprevir®. From 1998 to 2002, Dr. Blatt was Vice President of Research at SIRNA (formerly Ribozyme Pharmaceuticals). From 1996 to 1998, Dr. Blatt served as Vice President, Product Development at National Genetics Institute, (currently a division of LabCorp). Dr. Blatt began his career at Amgen where he was ultimately Head of Interferon Research and also Development Team Leader for the consensus interferon product leading to an FDA approval of the drug Infergen®. Dr. Blatt earned his B.S. in Microbiology from Indiana University, a Master's in Business Administration at the California State University, Northridge and a Doctorate in Public Health at the University of La Verne, La Verne, Calif.   Jack Nielsen – Chairman of the Board Jack Nielsen, Partner, joined Novo A/S in 2001 and is located in San Francisco, CA. From 1990 to 2001 Mr. Nielsen held various positions in the Novo Nordisk business area which in 2000 became Novozymes A/S. Before joining Novo Ventures, Mr. Nielsen was for four years deeply involved in designing the R&D strategy for Novozymes’ activities in the cereal food area, resulting in the development and launch of novel recombinant lipase and amylase enzymes. Jack has furthermore been involved in collaborations with Procter & Gamble, Danisco, and Quest International to identify new enzymes for the detergent and cereal food industry. Prior hereto, he held positions in marketing and technical services in the textile and personal care area, and started his career in the field of large-scale manufacturing of enzymes. Mr. Nielsen serves on the board of directors of Cell Biosciences, Inc., MediQuest Therapeutics, Inc., Protein Forest, Inc., Reata Pharmaceuticals, Inc. and NeoMend, Inc., and he is a former director of Panacos Pharmaceuticals, Inc., Nuevolution A/S, and CardioOptics, Inc. Jack Nielsen obtained his MSc in 1990 from the Technical University of Denmark, and his Master in Management of Technology from the Center for Technology, Economics and Management in Copenhagen in 2000.   Dr. Campbell Murray, MD. – Board Member Dr. Murray is a Managing Director of the Novartis Venture Funds in Cambridge, MA, USA. Prior to joining the venture fund in 2005, he worked at the Novartis Institutes for BioMedical Research as the director of special projects reporting to the president & CEO. Campbell, is a trained physician, Kauffman Fellow and holds an MBA with distinction from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government where he was a Knox Fellow and Rotary Ambassadorial Scholar. Dr Murray serves as a director on the boards of Aileron Therapeutics, Akebia Therapeutics, BioRelix, and ProCertus BioPharm and as an observer on the board of MicroCHIPS and Tepha.   Kent Gossett, DVM, Ph.D. - Board Member Dr. Gossett is a Partner of SR One in Conshohocken, PA, USA. Kent joined SR One in 2003. He is a member of the Board of Directors of CalciMedica and Locus Pharmaceuticals and an Observer for Scynexis Pharmaceuticals. He was previously Director of Protez Pharmaceuticals, Algeta ASA, and Alere Medical and Observer for Morphotek. Kent has 20 years experience in the pharmaceutical industry in safety assessment, drug development, business development and venture capital. Kent received his DVM and MS from Purdue University, his PhD in Veterinary Clinical Pathology from Louisiana State University, and his MBA from the Wharton School of the University of Pennsylvania.   Peter Hirth, Ph.D. – Board Member Dr. Hirth co-founded Plexxikon in December 2000, and has 20 years of biotechnology and pharmaceutical discovery and development experience. Previously, he was president of Sugen, Inc. until the sale of the company to Pharmacia Corporation in 1999. At Sugen, he helped build the company from its inception and advanced several kinase inhibitors through clinical trials for the treatment of oncology. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company's erythropoietin program. Previously, he also was a research scientist with the Max Planck Institute, following the completion of his post doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany.   Alios BioPharma: Management Team Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Management Team Lawrence Blatt, Ph.D., MBA – Founder, President & CEO Dr. Lawrence Blatt has spent the last 28 years working in drug research and development with a specific focus on biology of the immune system, antiviral therapies and relevant therapeutic interventions. From 2002-2008, Dr. Blatt was the Chief Scientific Officer of InterMune, Inc. and led the discovery and development of Danoprevir®. From 1998 to 2002, Dr. Blatt was Vice President of Research at SIRNA (formerly Ribozyme Pharmaceuticals). From 1996 to 1998, Dr. Blatt served as Vice President, Product Development at National Genetics Institute, (currently a division of LabCorp). Dr. Blatt began his career at Amgen where he was ultimately Head of Interferon Research and also Development Team Leader for the consensus interferon product leading to an FDA approval of the drug Infergen®. Dr. Blatt earned his B.S. in Microbiology from Indiana University, a Master's in Business Administration at the California State University, Northridge and a Doctorate in Public Health at the University of La Verne, La Verne, Calif.   Leonid Beigelman, Ph.D. – Founder, Chief Scientific Officer Dr. Beigelman has 26 years experience in medicinal chemistry and drug discovery with specific expertise in nucleotide and nucleoside chemistry. From 2005-2009, Dr. Beigelman served as Vice President of Medicinal Chemistry at InterMune, Inc. leading several teams in HCV drug discovery. From 2002 to 2005 Dr Beigelman worked at Transgenomic, Inc. as Vice President of Nucleic Acids Chemistry where he established large scale facility for GMP manufacturing of oligonucleotides and building blocks for oligonucleotide synthesis. While at Ribozyme Pharmaceuticals from 1992-2002 (now SiRNA) Dr Beigelman assumed positions of increasing responsibility culminating in appointment as Senior Director of Chemistry and Biochemistry. He initiated and led transition from ribosyme to siRNA technology that resulted in Merck acquisition of SiRNA. In 1991, Dr. Beigelman joined United States Biochemical as a research scientist and participated in the formation of Ribozyme Pharmaceuticals Inc. Dr. Beigelman received his PhD in Bioorganic Chemistry from The Institute of Molecular Biology (USSR Academy of Sciences) and completed his Post Doctoral training at the Department of Pharmacology, Yale University Medical School.   John Donovan – Founder, Chief Business Officer  John Donovan serves as Chief Business Officer of Alios BioPharma, Inc., and has over 15 years experience in biotechnology and investment banking.  Prior to joining Alios, Mr. Donovan was the Chief Financial Officer of CoMentis, Inc., where he was responsible for building the finance organization, raising capital, strategic planning and managing information technology, facilities and administration.  He previously held various senior management positions within InterMune, Inc., most recently as Vice President of Strategic Planning & Analysis.  During his tenure at InterMune, Mr. Donovan had been responsible for business analysis, strategy, long-term financial planning, investor relations and public relations.  Prior to InterMune, Mr. Donovan served as Vice President of Biotechnology Investment Banking at Banc of America Securities LLC, and he began his career in investment banking at Vector Securities International (subsequently Prudential Vector Healthcare) where he was involved in more than a dozen merger transactions and nearly two-dozen public and private capital raising transactions.   Mr. Donovan received his degree in Business Administration from the University of Notre Dame.   Alios BioPharma: Overview Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Overview Alios BioPharma is a biotechnology company located in South San Francisco, California, that is developing novel medicines aimed at the treatment of viral diseases. Alios has an innovative team of highly experienced scientists and clinical researchers who are developing direct acting antiviral agents against several human viral pathogens of public health importance including, hepatotropic viruses, respiratory viruses and other chronic, acute and emerging viral diseases. Additionally, Alios is developing molecular activators of an interferon induced, broad spectrum antiviral innate immune pathway called RNase-L.  The overall goal for the Alios therapeutic platform is to maximize patient benefits in areas of high unmet medical need through optimization of potency, safety and tolerability. Alios has a staff of 30 full time employees, of which 24 are scientists, working in a 20,000 square foot facility. Alios management has discovered or led the development of numerous compounds that have reached the clinic for the treatment of chronic hepatitis C. We are funded by an experienced group of Venture Capital backers with extensive industry experience including: Novo A/S, Novartis Ventures, Roche Ventures, and SR-One (GlaxoSmithKline ventures). Alios BioPharma: Home Home About Us Overview Management Team Board of Directors Scientific Advisors Technology Overview Activators of innate immunity Nucleoside Analogs News Room Press Releases Scientific Publications Career Opportunities Overview Research Associate, Respiratory Virology Contact Info Overview Management Team Board of Directors Scientific Advisors Home Alios is a biotechnology company located in South San Francisco, California, that is developing novel medicines that treat viral diseases. Alios has two platform technologies: novel nucleoside/nucleotide chemistries and small molecule activators of the RNase-L pathway. Copyright 2011 Alios BioPharma, All Rights Reserved.